Industry: Healthcare
Published Date: February-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 297
Report ID: PMRREP16510
The global revenue from the Hematology Analyzers Market was around US$ 1.31 Billion in 2022, with the global market expected to grow at a CAGR of 4.8% to reach a valuation of about US$ 2.20 Billion by the end of 2033.
| Attributes | Key Insights |
|---|---|
|
Market Size (2023) |
US$ 1.37 Billion |
|
Projected Market Value (2033) |
US$ 2.20 Billion |
|
Global Market Growth Rate (2023 to 2033) |
4.8% CAGR |
|
Market Share of Top 5 Countries |
65.9% |
As assessed by Persistence Market Research, 5-part hematology analyzers held a market share of around 72.8% in the global market, in 2022. Overall, hematology analyzers market sales account for around 38.0% of revenue share in the Global Haemotology Diagnostics market, which was valued at around US$ 3.5 Billion in 2022.
The global market recorded a historic CAGR of 3.9% in the last 7 years from 2015 to 2022.
More information can be provided by advanced hematology analyzers, both quantitatively and qualitatively, such as suspicious flags (used to detect errors). It is more effective to have access to real-time graphical data since it gives information on aberrant cell populations and illness patterns. The global population is using hematological analyzers on broader scale as a result of this technical improvement.
The global market is anticipated to grow at a rapid rate throughout the forecast period as a result of the continuously expanding research and development efforts in a number of fields, including stem cell research, gene therapies, targeted therapies, blood disorders, thalassemia, and omics. Owing to this trend the market will continue to thrive over the forecast period as well. The growth is also attributed to a variety of factors, including increased public awareness and the presence of numerous diagnostic facilities.
Leading manufacturers are concentrating on innovation-based approaches, utilising opportunities for scientific development with advancements in the field of diagnostics and testing. The introduction of new technological developments and the development of cellular analysis software has improved the effectiveness of analysis and data management, which has resulted in greater sales.
The market is expected to be driven by increasing chronic disease awareness around the world over the forecast period. Chronic diseases are the primary cause of death and illnesses across the globe. People from all socioeconomic classes are being affected by the rising prevalence of chronic diseases on a global scale. In the future, more hematology analyzers will be utilized by people for early diagnosis and treatment of such diseases in order to slow down the progression rate of such diseases.
The global market is likely to show high growth over the coming years at a CAGR of 4.8% and reach a global market size of US$ 2.20 Billion by 2033.
“Increasing Cases of Blood Disorders in Infants and Constant Product Innovation to Offer Lucrative Opportunities for the Market”
Over the past years, blood analysis has become more popular for the early diagnosis of several chronic diseases, which were previously only achievable through tissue biopsy studies. Hematology analyzers market growth is significantly influenced by improvements in blood indicators for diseases.
More than 1,125,000 men globally had an inherited bleeding problem, and over 418,000 of those had a severe form of the most undiagnosed disease, according to a World Federation of Hemophilia, July 2022. The safest way to protect a patient with blood disorders and maintain the quality of life is by early diagnosis and treatment. Therefore, the market is projected to be driven in the future by the rising burden of blood disorders.
Furthermore, it is predicted that the market will also rise in the future due to the increasing adoption rate of automated hematology analyzers and the integration of AI-based hematology analyzers along with growing preferences towards high sensitivity hematology testing.
Furthermore, automation has initiated more opportunities in the market by encouraging the development of new instruments like automated erythrocyte sedimentation rate (ESR) systems, integrated slide-makers, HbA1c systems, tube sorters, and electronic morphology systems that are connected to middleware. This continuous product innovation and their commercialization will create high demands for haematology analyzers throughout the forecast period.
“High Cost of the Products and Stringent Regulatory Scenario to Impede the Market Growth”
Modern products available on the market are not accepted or preferred in underdeveloped countries. Another significant factor is product recalls and concerns about the product's efficacy and safety, this factor is anticipated to limit the market's growth. Lack of preference, which slows this device's adoption in developing nations, is a factor that restricts market growth.
Market growth is anticipated to be restricted over the anticipated period by competitiveness between current players and the high cost of haematology analyzers. Additionally, it is anticipated that the market would not expand during the projected period due to the time-consuming and stringent regulatory standards for hematology analyzers.
Why is the United States Market Booming?
“Rising Prevalence of Blood Disorders and Increased Adoption Rates of the Hematology Analyzers”
The United States accounted for around 90.3% market share in the North America market in 2022.
Due to the rising prevalence of blood disorders in the country, the U.S. is predicted to account for the greatest portion of the market in terms of revenue. For instance, the WHO estimates that more than three million U.S. citizens, mostly young women, suffer from anemia, a common blood disorder. Future market expansion is also anticipated to be fueled by the increased acceptance of hematology analyzers by the diagnostic sector and the country's technological advancements in diagnostic instruments.
Will the U.K. Be a Lucrative Market for Hematology Analyzers?
“Presence of Major Players and Well Developed Research and Development Sectors”
The U.K. market held around 24.3% market share of the Europe market in 2022.
High emphasize on research and development activities in the analysing analyzers industry with constant product development and innovation coupled with presence of well-established players and high government expenditures will lead to market expansion in the U.K. over the forecast period.
How is China Emerging as a Prominent Market?
“Increasing Utilization of Automated Hematology Instruments”
China held a market share of about 50.2% of the East Asia market in 2022.
The market is expected to grow due to the increased frequency of thalassemia in the general population, rising adoption rates of automated hematology instruments, and rising demand for high sensitivity point-of-care (POC) haematology testing.
Thus, the rising cases of blood disorders will create lucrative demands for the market and uplift the sales in the coming times.
Which Product is Driving Demand within the Global Market?
“Better Efficacy in Providing Clinical Information”
The 5-part segment held around 72.8% share of the total market in 2022.
Throughout the forecast period, it is projected that the 5-part hematology analyzers segment would hold the dominant market share, owing to the fact that it is very affordable and offers information sufficient for the majority of clinical situations. In order to identify a variety of clinically significant conditions, such as autoimmune diseases and infections, 5-part analyzers offer crucial clinical information that is not possible with a 3-part analyzers.
Why Standalone Hematology Analyzers Are Largely Adopted within the Global Market?
“Better Handling of Large Quantity of Sample at Once with Efficient and Accurate Handling”
Standalone segment held around 54.3% share of the total market in 2022.
In comparison to point-of-care hematology analyzers, standalone hematology analyzers have a number of advantages, including the ability to handle a high quantity of samples efficiently and quickly, accuracy and precision in quantitative blood tests, the ability to run multiple tests on a single platform, a significant reduction in labor costs, and an unmatched ability to accurately determine red cell indices.
These machines are commonly used in healthcare environments like hospitals and diagnostic centres because of their effective features and these devices perform and handle multiple samples at once.
Which End User Predominantly Utilizes the Hematology Analyzers?
“Large Patient Pool Suffering from Blood Related Disorders Preferring in-Hospital Care”
Hospitals segment held around 42.7% share of the total market in 2022.
Chronic lead poisoning and sickle cell disease, as well as the rising prevalence of blood-related disorders like hereditary spherocytosis and cytochemistries on blood and bone marrow, all contribute to the dominance of hospitals segment in the market. Patients with such disorders choose to receive care and treatment in hospitals because of the presence of highly sophisticated equipment and technologies and care from medical professionals.
The majority of players are extremely committed to the development of novel products. In the last ten years, 6-part and 4-part hematology analyzers have been introduced, providing end users with more options to meet their needs. Along with this, a lot of attention is being paid to the creation of new features and automation of tools like 3D scatter maps and suspect mapping. Another important area of focus for market players in hematology analyzers is partnerships with distributors, which will improve product penetration globally.
Some key instances of development include:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the hematology analyzers market, which are available in the full report.
| Attribute | Details |
|---|---|
|
Forecast Period |
2023 to 2033 |
|
Historical Data Available for |
2015 to 2022 |
|
Market Analysis |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Covered |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Product:
Modality:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is currently valued at around US$ 1.31 Billion in 2022.
Sales of the market are set to witness growth at a CAGR of 4.8% and be valued at around US$ 2.20 Billion by 2033.
Demand for the global market increased at a 3.9% CAGR from 2015 to 2022.
The U.S., China, Japan, the U.K., and France account for most demand within the market, currently holding around 65.9% market share.
The U.S. accounts for around 90.3% share of the North American market in 2022.
Latin America accounts for around 5.9% share of the global market in 2022.
The China market held a share of about 50.2% in the East Asia hematology analyzers market in 2022.
The U.K. hematology analyzers market is set to expand at 4.8% CAGR over the forecast period.
SYSMEX CORPORATION, Abbott Laboratories, Beckman Coulter Inc., Siemens AG are among some of the prominent players operating in the global market.
Rising prevalence of blood related disorders coupled with increasing adoption of automated hematology analyzers are few of the drivers that are propelling the global market.
